Why the study?
Does viral IL-10 gene transfer reduce the severity of collagen-induced arthritis in DBA/1 mice?
Does viral IL-10 gene transfer reduce the severity of collagen-induced arthritis in DBA/1 mice?
Viral IL-10 gene transfer can delay onset and reduce severity of collagen-induced arthritis in mice when given prophylactically, but is ineffective for established disease and elicits immune responses against the vector.
Answers are grounded in this paper and cite their sources.
Prophylactic vIL-10 gene transfer attenuates murine CIA; leaves open translation to humans and utility in established disease.
Autoimmune arthritides are characterized by an imbalance between pro- and anti-inflammatory cytokines. Viral IL-10 (vIL-10) shares many of the anti-inflammatory properties of mouse and human IL-10, but lacks their immunostimulatory properties and may therefore offer superior immunosuppression. Viral IL-10 has a short half-life; however, genetic modification of cells in vivo offers a potential means of achieving prolonged therapeutic titers. To determine the effects on collagen-induced arthritis of vIL-10 gene transfer, DBA/1 mice were administered i.v. or intra-articular injections of Av(vIL-10), a replication-deficient adenovirus encoding vIL-10. The i.v. injection of Av(vIL-10) before disease onset delayed the onset and reduced the severity of collagen-induced arthritis, but treatment of established disease was ineffective. The preventative effects were not due to decreased anti-type II collagen Ab production. Rather, T cells from mice treated with Av(vIL-10) demonstrated a decreased in vitro proliferative response to type II collagen, and a delay was observed in up-regulation of synovial mRNA for the proinflammatory cytokines IL-2 and IL-1beta. Intra-articular injection of Av(vIL-10) into knee joints did not reduce arthritis in the knees, but inhibited the development of arthritis in the paws. Humoral and cellular immune responses against Av(vIL-10) were observed. These results demonstrate that vIL-10 can significantly alter the course of autoimmune arthritis and emphasize the complexities of using gene transfer as a method of drug delivery for arthritis.
No takes yet. Share an insight, caveat, or question.
Ma et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: